Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21028082 | 0.80 | NR1H2 (0.35) | NR1H2NR1H3SIGMAR1NOTUMCA12 | |
| SCHEMBL3542987 | 0.79 | NOTUM (0.40) | NR1H2NR1H3SIGMAR1NOTUMCA12 | |
| SCHEMBL928229 | 0.78 | HPGD (0.38) | CASP3 | |
| SCHEMBL928181 | 0.78 | HPGD (0.38) | CASP3 | |
| SCHEMBL30684094 | 0.77 | CYP1A2 (0.40) | OPRM1OPRD1OGFRL1SIGMAR1NOTUM | |
| SCHEMBL21028027 | 0.71 | KMT2A (0.37) | NOTUM | |
| SCHEMBL12598328 | 0.68 | HTR2A (0.38) | NR1H2SIGMAR1 | |
| SCHEMBL21028020 | 0.68 | HTR2A (0.38) | OPRM1OPRD1SIGMAR1NOTUM | |
| SCHEMBL12598321 | 0.68 | NOTUM (0.42) | NR1H2NR1H3NOTUMCA12CA9 | |
| SCHEMBL13279458 | 0.67 | CCR9 (0.34) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-12-13 | — | — | US | disclosed |
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| EP-3489235-A1 | TRICYCLIC COMPOUND AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | NR3C2, CRHR2, CRHR1 | NR1H2 4/4885CASP3 4779/4885OPRM1 1866/4885 |
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | NR1H2, NR3C2, NR1H4 | NR1H2 1/4885CASP3 4679/4885OPRM1 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.